Compass Therapeutics (CMPX) Stock Forecast & Price Target

Compass Therapeutics Inc is making significant strides in its clinical pipeline, particularly with CTX-8371, which shows a differentiated safety profile and multi-indication activity that could expand its market presence into areas such as non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The company has reported a robust financial position with $101 million in cash, providing ample runway to support ongoing research and development efforts, even with a notable increase in R&D expenses of 49% to $12.8 million indicating a commitment to advancing its therapeutic candidates. The promising clinical updates, particularly from the Phase 2/3 tovecimig trial in advanced biliary tract cancer showing fewer deaths than expected, position Compass Therapeutics favorably for potential positive overall survival outcomes and enhance investor confidence in its future performance.

Compass Therapeutics Inc. reported a net loss of $14.3 million in Q3 2025, an increase from $10.5 million in Q3 2024, driven by elevated research and development expenses related to the manufacturing of CTX-10726 and IND-enabling studies. The challenges posed by small cell lung cancer (SCLC), which is aggressive and associated with poor survival rates in relapsed and refractory situations, raise concerns about the efficacy and market potential of the company's therapeutic candidates targeting this condition. Additionally, the rising costs associated with R&D efforts, coupled with the grim prognosis of the targeted disease, contribute to a negative outlook on the company's financial performance.